Pharmaceuticals, Biotechnology and Life Sciences
$3.3M in revenue representing 108% Y-Y growth, significant growth in finished product sales Total of 4 brands, 16 SKU’s and…
Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022 BASKING RIDGE, NJ, March 31, 2022 (GLOBE NEWSWIRE)…
Orphazyme A/S in restructuringCompany announcementNo. 16/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 31, 2022 – Orphazyme A/S in restructuring (ORPHA.CO)…
MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the…
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH…
Advances U.S. Clinical Trials for T2Biothreat and T2Resistance and Continued Development of Next-Generation Diagnostics for the Detection of Bloodstream Infections…
SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage…
MISSISSAUGA, Ontario, March 31, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its…
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ETSAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE)…
Company to host investor update call Thursday, April 7, at 4:30 p.m. ET BOSTON, March 31, 2022 (GLOBE NEWSWIRE) —…